Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-life use of delamanid: results from the European post-authorisation safety study.

Autor: Schönfeld N; Helios Klinikum Emil von Behring, Berlin, Germany., Barkane L; Riga East University Hospital, Riga, Latvia., Davoliene I; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Danilovits M; Tartu University Hospital, Tartu, Estonia., Miliauskas S; Department of Pulmonology, Lithuania University of Health Sciences, Kaunas, Lithuania., Ader F; Hospices Civils de Lyon, Département des Maladies Infectieuses et Tropicales, Lyon, France., Kon OM; Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK., Lange C; Research Center Borstel, Leibniz Lung Center, Borstel, Germany.; Tuberculosis Unit, German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel Riems, Borstel, Germany.; Respiratory Medicine & International Health, University Lübeck, Lübeck, Germany.; Baylor College of Medicine and Texas Children´s Hospital, Global TB Program, Houston, TX, USA., Duvignaud A; Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Bordeaux-Groupe Hospitalier Pellegrin, Bordeaux, France., Heiss-Neumann M; Asklepios Fachkliniken München-Gauting, Gauting, Germany., Hittel N; Otsuka Novel Products, Munich, Germany., Lazarević N; Otsuka Novel Products, Munich, Germany., Knebel I; Otsuka Novel Products, Munich, Germany., Martin A; Otsuka Novel Products, Munich, Germany., Eschenbach B; Otsuka Pharma, Frankfurt, Germany., van Heumen E; Otsuka Pharma, Frankfurt, Germany., George V; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ, USA.

Publikováno v: IJTLD open [IJTLD Open] 2024 Jun 01; Vol. 1 (6), pp. 274-278. Date of Electronic Publication: 2024 Jun 01 (Print Publication: 2024).